DSpace Repository

Cycloserine-induced psychosis in patients with drug-resistant tuberculosis: a systematic review of case reports

Show simple item record

dc.contributor.author Cotrina Santome, Edgar Alonso
dc.contributor.author Ulloa Esquivel, Lizbeth
dc.contributor.author Vásquez Quispe, Shirley Pierina Saouri
dc.contributor.author Arévalo Flores, Jorge Martín
dc.contributor.author Pedraz Petrozzi, Bruno
dc.date.accessioned 2023-04-16T04:38:12Z
dc.date.available 2023-04-16T04:38:12Z
dc.date.issued 2023
dc.identifier.uri https://hdl.handle.net/20.500.12866/13361
dc.description.abstract Objectives: To describe the clinical characteristics and outcomes of cycloserine (CS)-induced psychosis in adults diagnosed with drug-resistant tuberculosis (DR-TB). Materials and methods: A systematic review of case reports was carried out according to PRISMA guidelines. Subsequently, information was extracted concerning sociodemographic variables, clinical characteristics of psychosis, treatment, and clinical outcomes, as well as the quality of the articles using a standardized tool (Joanna Briggs Institute—JBI—Case Reports Tool). Results: Of 3416 articles, 20 reports from seven countries were included, encompassing 22 patients (68.18% male participants, mean age: 31.45 ± 10.88 years). Delusions (68.2%, primarily persecutory) were the most frequent psychotic symptom. The median duration of the psychotic episode was 13 days (interquartile range: 35). Other frequently appearing symptoms in CS-induced psychosis were aggressiveness (68.2%), insomnia (59.1%), hallucinations (54.5%), incoherent/disorganized speech (45.5%), and irritability (45.5%). After antipsychotic treatment (81.81% of the reported cases were treated with at least one antipsychotic), 95.5% presented improvement, while 4.54% died by suicide. Finally, after the quality assessment of studies using the JBI tool, 85% of the articles showed a low risk of bias. Conclusions: CS-induced psychosis is a rare presentation, generally of short duration, that includes delusions (mostly persecutory) as its main psychotic symptom and shows mostly a symptom improvement after medical treatment. Trial registration PROSPERO registration number: CRD42022359551 (Date of registration: 22/09/2022) © 2023, The Author(s). en_US
dc.language.iso eng
dc.publisher Springer
dc.relation.ispartofseries Egyptian Journal of Neurology, Psychiatry and Neurosurgery
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Tuberculosis en_US
dc.subject Systematic review en_US
dc.subject Cycloserine en_US
dc.subject Extensively drug-resistant tuberculosis en_US
dc.subject Multidrug-resistant en_US
dc.subject Psychoses en_US
dc.subject Substance-induced en_US
dc.title Cycloserine-induced psychosis in patients with drug-resistant tuberculosis: a systematic review of case reports en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.1186/s41983-023-00642-6
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.01.04
dc.relation.issn 1687-8329


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics